Reason for request
Re-assessment of the actual benefit at the request of the Transparency
Clinical Benefit
Low |
Le service médical rendu par MEGACE 160 mg est faible dans le traitement palliatif des carcinomes du sein.
|
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
wn3jveD4NLrEUJM5